Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial
- DOI
- 10.1159/000553375
- Published
- 2026-07-04
- Container
- Liver Cancer
- Publisher
- S. Karger AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1159/000553375,
title = {Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial},
author = {Masatoshi Kudo and Arndt Vogel and Thomas R. Jeffry Evans and Yuk Ting Ma and Bruno Daniele and Ari David Baron and Amit Mahipal and Shukui Qin and Jean Frederic Blanc and Carlos Lopez Lopez and Ann-Lii Cheng and Su Pin Choo and Fabio Piscaglia and Kalgi Mody and Min Ren and Stephen Lam Chan},
year = {2026},
journal = {Liver Cancer},
doi = {10.1159/000553375},
url = {https://doi.org/10.1159/000553375}
}RIS
TY - JOUR TI - Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial AU - Masatoshi Kudo AU - Arndt Vogel AU - Thomas R. Jeffry Evans AU - Yuk Ting Ma AU - Bruno Daniele AU - Ari David Baron AU - Amit Mahipal AU - Shukui Qin AU - Jean Frederic Blanc AU - Carlos Lopez Lopez AU - Ann-Lii Cheng AU - Su Pin Choo AU - Fabio Piscaglia AU - Kalgi Mody AU - Min Ren AU - Stephen Lam Chan PY - 2026 JO - Liver Cancer DO - 10.1159/000553375 UR - https://doi.org/10.1159/000553375 ER -
APA
Kudo, M., Vogel, A., Evans, T. R. J., Ma, Y. T., Daniele, B., Baron, A. D., Mahipal, A., Qin, S., Blanc, J. F., Lopez, C. L., Cheng, A., Choo, S. P., Piscaglia, F., Mody, K., Ren, M., & Chan, S. L. (2026). Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial. Liver Cancer. https://doi.org/10.1159/000553375
Source records
- crossref · retrieved 2026-11-10T08:38:26.714Z